Endoprostheses

Abstract

Endoprosthesis are disclosed.

1 . (canceled) 
     
     
         2 . The method of  claim 23 , wherein the coating further includes a therapeutic agent. 
     
     
         3 . The method of  claim 2 , wherein the coating includes between about 1 percent by weight and about 35 by weight therapeutic agent. 
     
     
         4 . The method of  claim 2 , wherein the therapeutic agent inhibits restenosis. 
     
     
         5 . The method of  claim 4 , wherein the therapeutic agent that inhibits restenosis comprises paclitaxel. 
     
     
         6 . The method of  claim 2 , wherein the polymeric material fully releases its therapeutic agent in less than seven days in blood at body temperature. 
     
     
         7 . The method of  claim 23 , wherein the polymeric material fully degrades in less than 365 days in blood at body temperature. 
     
     
         8 . The method of  claim 23 , wherein the polyol is selected from the group consisting of be polyethylene glycol, polycaprolactone polyol, polycyclooctene polyol, trans-1,4 butadiene polyol, transisoprene polyol, polynorbornene polyol, polymethacrylate copolymer polyol, polycaprolactone-polylactide copolymer polyol, polycaprolactone-polyglycolide copolymer polyol, polycaprolactone-polylactide-polyglycolide copolymer polyol, polylactide polyol, polycaprolactone-poly(β-hydroxybutyric acid) copolymer polyol, poly (β-hydroxybutyric acid) polyol, and mixtures thereof. 
     
     
         9 . The method of  claim 23 , wherein the polyol has only two pendent hydroxyl groups, and wherein the hydroxyl groups are disposed at ends of the polyol. 
     
     
         10 . The method of  claim 23 , wherein the isocyanate comprises a diisocyanate. 
     
     
         11 . The method of  claim 10 , wherein the diisocyanate is selected from the group consisting of 4,4′-diphenyl methylene diisocyanate, toluene-2,4-diisocyanate, toluene-2,6-diisocyanate, hexamethylene-1,6-diisocyanate, isophorone diisocyanate, and hydrogenated 4,4′-diphenylmethylene diisocyanate, and mixtures thereof. 
     
     
         12 . The method of  claim 23 , wherein the silsesquioxane selected from the group consisting 1-(2-trans-cyclohexanediol)ethyl-3,5,7,9,11,13,15-isobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxane, 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy methyl]propane-1,3-diol, 1-(2,3-propanediol)propoxy-3,5,7,9,11,13,15-isobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxane, 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy]methyl]-1,3-propanediol, and mixtures thereof. 
     
     
         13 . The method of  claim 23 , wherein a weight ratio of the polyol to the silsesquioxane is from about 1:2 to about 1:30. 
     
     
         14 . The method of  claim 23 , wherein the coating has a thickness of between about 3 micron and about 50 micron before the implantable endoprosthesis is expanded. 
     
     
         15 . The method of  claim 23 , wherein a coverage of the polymeric material on the tubular member is from about 0.1 μg per square millimeter of surface area of the tubular member to about 10 μg per square millimeter of surface area of the tubular member. 
     
     
         16 . The method of  claim 23 , wherein the tubular member comprises a material selected from the group consisting of alloys, bioresorbable metals, metal oxides, bioresorbable polymers, and mixtures thereof. 
     
     
         17 . The method of  claim 23 , wherein the polymeric material has an absolute molecular weight of greater than about 50,000. 
     
     
         18 . (canceled) 
     
     
         19 . The method of  claim 23 , wherein the polyol has an absolute molecular weight of from about 5,000 to about 20,000. 
     
     
         20 . The method of  claim 23 , wherein the polymeric material has a glass transition temperature of less than 100° C. 
     
     
         21 . The method of  claim 23 , wherein the polymeric material has a glass transition temperature of within about 10° C. of nominal human body temperature. 
     
     
         22 . The method of  claim 23 , wherein the polymeric material has a storage modulus at 25° C. of less than 1,000 MPa. 
     
     
         23 . A method of treating a cavity or lumen in a mammal, the method comprising:
 implanting, into the lumen or cavity of the mammal, an endoprosthesis comprising a tubular member having a coating comprising a polymeric material including a reaction product of a polyol, an isocyanate and a silsesquioxane having at least two pendent hydroxyl groups.   
     
     
         24 . The method of  claim 23 , wherein the method further includes expanding the endoprosthesis. 
     
     
         25 . The method of  claim 23 , wherein the lumen is a vascular lumen. 
     
     
         26 - 37 . (canceled) 
     
     
         38 . The method of  claim 24 , wherein the expanding in performed with a balloon. 
     
     
         39 . The method of  claim 24 , wherein the endoprosthesis is self-expanding. 
     
     
         40 . The method of  claim 2 , wherein the therapeutic agent comprises everolimus.